Upcoming Financial Results from InflaRx
InflaRx N.V., a pioneering biopharmaceutical firm based in Germany, is preparing to share its second quarter 2025 financial and operational results on August 7, 2025, ahead of market operations. Noteworthy is that no conference call is scheduled alongside this announcement.
About InflaRx and Its Innovations
InflaRx N.V. focuses on developing advanced anti-inflammatory therapeutics. By targeting the complement system, the company aims to introduce groundbreaking treatment options for inflammatory diseases. InflaRx has notably developed vilobelimab, a first-in-class, intravenously delivered monoclonal antibody that specifically binds to free C5a, a significant player in inflammation-driven conditions.
The Mechanism Behind C5a Inhibition
C5a acts as a potent inflammatory mediator, influencing the progression of numerous inflammatory diseases. The ability of vilobelimab to modify disease states has been evidenced through multiple clinical trials, highlighting both its clinical efficacy and tolerability.
Future Developments at InflaRx
In addition to vilobelimab, InflaRx is developing INF904, an innovative small molecule that inhibits C5a-induced signaling through its receptor. This is pivotal for broadening therapeutic applications in the future. The impact of these innovations positions InflaRx as a key player in the biopharmaceutical space focused on limited C5a activity that significantly affects inflammation.
Company Background
Founded in 2007, InflaRx N.V. operates with a dedicated goal of alleviating the burden of inflammatory diseases through innovative biologics. The company boasts prominent locations in Jena and Munich, Germany, along with a subsidiary office in Ann Arbor, MI, USA.
Company Contacts
Communication plays a critical role in a company’s transparency. InflaRx provides various channels for engagement:
- Jan Medina, CFA
Vice President, Head of Investor Relations
Email: IR@inflarx.de - MC Services AG Contacts:
Katja Arnold, Laurie Doyle, Dr. Regina Lutz
Email: inflarx@mc-services.eu
Europe: +49 89-210 2280
U.S.: +1-339-832-0752
Frequently Asked Questions
1. What are the main products developed by InflaRx?
InflaRx specializes in anti-inflammatory therapeutics, particularly vilobelimab, an anti-C5a monoclonal antibody, and INF904, a small molecule inhibitor.
2. When will InflaRx report its financial results?
InflaRx will announce its second quarter financial results on August 7, 2025.
3. How can I learn more about InflaRx's stock performance?
You can visit InflaRx's official website for the latest updates and detailed information about its stock performance.
4. Does InflaRx conduct investor calls?
No investor conference call is scheduled in conjunction with their upcoming financial results announcement.
5. Where is InflaRx located?
InflaRx has offices in Jena and Munich, Germany, along with a subsidiary in Ann Arbor, MI, USA.